TROPION-Lung01 Study Design and Baseline demographics
Preliminary efficacy data for R-DXd are promising in pretreated OVC patients
Best % change from baseline in
sum of diameters of target lesions
Data cutoff: July 14, 2023.
*CR + PR + stable disease.
80
•
60
40
40
20
20
-20
40
-60
-80
-100
0.
☐
•
Confirmed ORR: 46% in the 4.8-8.0 mg/kg OVC cohort (23/50; 95% CI: 32–61); one CR and 22 PRs
。 4 unconfirmed responses were ongoing at data cutoff
Disease control ratea: 98%
4.8 mg/kg
8.0 mg/kg
Starting dose level
| 4.8 mg/kg (n=9)
5.6 mg/kg (n=4)
6.4 mg/kg (n=23)
8.0 mg/kg (n=13)
The efficacy evaluable population included patients who received 21 dose of study treatment and completed 21 post-baseline tumor assessment or discontinued treatment for any reason. Change from baseline in target tumor size was assessed per RECIST v1.1.
Two patients with no measurable lesions at baseline and one patient who discontinued and did not have a post-baseline tumor assessment were not included in the waterfall plot.
CI, confidence interval; CR, complete response; ORR, objective response rate; OVC, ovarian cancer; PR, partial response; RECIST v1.1, Response Evaluation Criteria in Solid Tumors version 1.1.
57
40
Daiichi-SankyoView entire presentation